Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon
Mené sur 1 670 patients atteints d'un mélanome à haut risque de récidive ayant été réséqué, cet essai de phase III compare l'efficacité, du point de vue de la survie globale et de la survie sans récidive, et la toxicité de l'ipilimumab (3 ou 10 mg/kg) et de hautes doses d'interféron alpha en traitement adjuvant
Before the immune checkpoint blockade era, patients with surgically resected, high-risk melanoma faced difficult prognoses. Recurrence rates were high, overall survival (OS) was poor, and treatment options were limited to interferon alfa-2b. Interferon offered patients improvement in recurrence-free survival (RFS), but its use was limited by significant adverse effects and controversial impact on OS.
Journal of Clinical Oncology , éditorial en libre accès, 2018